Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
High-throughput screening identifies RK-0080552 (RK-552) as a novel NSD2 inhibitor with cytotoxic activity against t(4;14)+ vs. t(4;14)- myeloma cells in vitro and in vivo via transcriptional suppression of the IRF4 gene.”
Title: Discovery of a novel class NSD2 inhibitor for multiple myeloma with t(4;14)+
Authors: Sae Matsuoka, Naoki Osada, Hirokazu Kubota, Ko Kikuzato, Hiroo Koyama, Takeshi Sonoda, Akiko Idei, Minoru Yoshida, Masaki Kikuchi, Takashi Umehara, Chiduru Watanabe, Teruki Honma, Hiroshi Yasui, Sho Ikeda, Naoto Takahashi, Hideki Nakasone, Jiro Kikuchi, Yusuke Furukawa
You can read the Full Article in Blood Neoplasia.
You can find more posts featuring Robert Orlowski on OncoDaily.
